ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/27/23 | $155,000,000 | Series B |
AIHC Capital Boyu Capital Catalio Capital Management General Catalyst Partners  HBM Healthcare Investments Infinitum Asset Management Lilly Asia Ventures Octagon Capital OrbiMed Advisors Sequoia China Shanghai Healthcare Capital Sirona Capital Sofinnova Ventures Terra Magnum Capital Partners Unicorn Capital Partners Limited | undisclosed |
